Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel. Show more

Building C, Tel Aviv-Yafo, 6158101, Israel

Biotechnology

Healthcare

Market Cap

20.15M

52 Wk Range

$1.35 - $3.58

Previous Close

$2.75

Open

$2.75

Volume

76,862

Day Range

$2.59 - $2.80

Enterprise Value

9.492M

Cash

6.687M

Avg Qtr Burn

N/A

Insider Ownership

12.19%

Institutional Own.

8.36%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nebokitug Details Primary Sclerosing Cholangitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nebokitug (CCL24 Blocking Antibody) Details Rheumatoid Arthritis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.